| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d5079c4242bfd5be471374b79ddcac22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c97f90ab12b35b650d5fd039ed7a41a5 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-4724
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2400-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2021-6417
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-96455 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N21-648
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N21-553
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57488
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57484
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57434 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N21-64
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 |
| filingDate |
2017-11-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e5167f77fec738b7da261bfeb341bea2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5cc90f5897ee958e87e9c61c9a14cb02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_12051892ee43f48c427e13212737fc75
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2508ae173f1a95f730a0c1bcd767953b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_11ee8d945315e9d723669f60be55a952 |
| publicationDate |
2019-10-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-3550304-A1 |
| titleOfInvention |
Method for estimating gleason score of prostate cancer, method for estimating pathological stage, and method for acquiring supplementary information, all on the basis of specific psa content in specimen |
| abstract |
The present invention provides methods that are for acquiring various types of supplementary information used for diagnosis or treatment of prostate cancer, and that can be implemented in a less-invasive manner at a low cost. Provided are, by measuring the content of prostate specific antigen (PSA) having a β-N-acetylgalactosamine residue at a non-reducing terminal of a sugar chain in a specimen, and comparing the measured value with a threshold value, (1) a method for estimating whether a Gleason score (primary pattern and secondary pattern) is not less than or less than a prescribed value, (2) a method for estimating whether the pathological stage (pT) is not less than or less than a prescribed value, and (3) a method for acquiring information for assessment indicating diagnosis or treatment should be actively conducted because a GS at gross total removal is expected to be higher than a GS at biopsy. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3550303-A4 |
| priorityDate |
2016-11-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |